gamma signature guidance in optimizing neoadjuvant immunotherapy for resectable melanoma
Published 10 months ago • 36 plays • Length 0:40Download video MP4
Download video MP3
Similar videos
-
3:15
optimal neoadjuvant io in resectable stage iii melanoma: interferon gamma signature analysis
-
1:22
the personalization of neoadjuvant immunotherapy in stage iii melanoma
-
1:20
neopele: neoadjuvant pembrolizumab and lenvatinib in resectable stage iii melanoma
-
3:09
advances in utilizing neoadjuvant immunotherapy in melanoma
-
0:35
potential advantages of neoadjuvant immunotherapy for melanoma
-
2:52
opacin-neo trial rfs and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
-
3:44
neoadjuvant approaches in melanoma
-
2:10
neoadjuvant therapy for melanoma
-
1:14
adjuvant and neoadjuvant clinical trials for melanoma
-
2:58
the importance of biomarkers to optimize treatment with immunotherapy for melanoma
-
5:18
neoadjuvant ipilimumab and nivolumab immunotherapy for resectable stage iii melanoma
-
5:38
neoadjuvant therapy with immunotherapy for stage iiib-d melanoma
-
8:55
studies back neoadjuvant strategies for melanoma
-
4:04
neoantigens for melanoma treatment
-
2:33
opacin-neo & prado 3-year results in stage iii melanoma: personalized neoadjuvant io benefits
-
1:15
melanoma advancements: immunotherapy in the adjuvant setting
-
2:57
identifying patients for neoadjuvant melanoma therapy
-
1:15
improving understanding of nevus development to better prevent, predict and detect melanoma